Fig. 4

Difference in the proportion of patients achieving a 20% improvement in the American college of Rheumatology composite (ACR20) score between treatment and placebo for (A) All included studies (B) studies with tofacitinib as experimental group and (C) studies with non-tofacitinib JAK inhabitors as experimental group